Search for: "losartan"
Results 61 - 74
of 74
Sorted by Relevance
|
Sort by Date
7 Mar 2011, 4:45 am
"***Related to switching, from the internetI received a call wanting me to switch from Diovan (valsartan) to generic losartan (branded drug Cozaar). [read post]
7 Jul 2010, 5:14 am
(Patent Docs) (Holman's Biotech IP Blog) US: AMP v USPTO after Bilski v Kappos (Patent Docs) US: NORD Chair/HP&M Director presents opening testimony at first ever FDA orphan drug hearing (FDA Law Blog) US: Celsis files patent infringement complaint against CellzDirect and Invitrogen over pooled multi-cryopreserved hepatocyte products (Patent Docs) Products Astelin (Azelastine) – US: Zydus admits infringing Meda’s Astelin patent, agrees not to market generic (Patent Docs)… [read post]
15 Dec 2010, 2:17 am
Becton, Dickinson & Co (Intellectual Property Law Blog) US: Regents of the University of California pursue new patent re-examination in District Court (Patents Post Grant Blog) US: Microsoft v i4i, the burden of proof and the pharma sector (PatLit) US: IRS issues notice to implement annual fee on brand drugs (FDA Law Blog) US: Bright ‘orphan’ ideas blossom (FDA Law Blog) US: Amicus briefs in AMP v USPTO (Patent Docs) (Patent Docs) (Patent Docs) US: University of California files for… [read post]
15 Jul 2009, 5:15 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM) US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period (FDA Law… [read post]
14 Apr 2010, 12:05 pm
” Following the frenetic losartan 180-day litigation – which is still not over, as FDA has filed a petition for panel rehearing and rehearing en banc of the D.C. [read post]
27 Mar 2024, 12:41 pm
Fla. 2022). [9] In re Valsartan, Losartan, and Irbesartan Prods. [read post]
9 Nov 2010, 9:49 pm
The November issue of Intellectual Property Magazine carries a special focus on media and sport, but the IPKat's recommendation in this issue is "Losartan: a modern parable of pharma patent lifecycle management" by Innovate Legal's Duncan Curley and Amanda Easey. [read post]
30 Jan 2020, 5:29 am
In 2018, there were also recalls of several generic medications used for high blood pressure and heart failure (including valsartan, losartan, and irbesartan) due to NDMA in some of those medications, which was attributed to defective manufacturing processes. [read post]
30 Jan 2020, 5:29 am
In 2018, there were also recalls of several generic medications used for high blood pressure and heart failure (including valsartan, losartan, and irbesartan) due to NDMA in some of those medications, which was attributed to defective manufacturing processes. [read post]
1 Apr 2010, 3:04 am
MDCO launches another lawsuit against the PTO over Angiomax PTE (FDA Law Blog) Arzerra (Ofatumumab) – US: Biogen files patent infringement suit in S D California against Glaxosmithkline based on manufacture and sale of Arzerra (Patent Docs) Arzerra (Ofatumumab) – US: Genetech files counterclaims in declaratory judgment suit brought by GlaxoSmithKline (Patent Docs) Astelin (Azelastine) – US: District Court New Jersey: Patent infringement complaint following Para IV challenge: Meda… [read post]
6 Apr 2011, 12:18 am
Laboratorios Rubió (EPLAW) Gemzar (Gemcitabine) – US: ITC: Target date of 23 July 2012 set in Certain Gemcitabine (ITC 337 Law Blog) Intuniv (Guanfacine) – US: Shire files patent infringement complaint based on Mylan’s ANDA filing (Patent Docs) Isentress (Raltegravir) – India: Cipla files for compulsory license against Merck’s Isentress (Spicy IP) Losartan, HCTZ – France: Cour d’appel confirms combination products infringe mono-SPCs and… [read post]
19 Jan 2011, 2:00 am
– Health Care Reform Bill (Patent Baristas) US: Academic study supports longer data exclusivity term for conventional drugs (Patent Docs) US: PTO sued after denying ‘mildly tardy’ second interim PTE request: Genetics & IVF Institute v Kappos (FDA Law Blog) US: AMP v USPTO – Appellees’ brief (Patent Docs) Products Avodart (Dutasteride) – US: GlaxoSmithKline file patent infringement complaint against Anchen following Para IV certification (Patent Docs)… [read post]
26 Dec 2022, 6:21 pm
It's not the border that is the problem but what happens after you cross.Challenges to the Application of the Chinese State Secrets Law Abroad as Sword or Shield--A First Cut in In Re Valsartan, Losartan, and Irbesartan Products Liability Litigation (US DC NJ). [read post]
1 Jul 2024, 8:00 am
Seventy percent of civil cases in federal court are in an MDL in 2024. [read post]
